spacer
home > directory > BENEO GmbH
PHARMACEUTICAL INDUSTRY DIRECTORY

BENEO GmbH

BENEO GmbH
Improve palatability of solid and liquid medicine with galenIQ™ – the sweet filler-binder that helps the medicine go down more easily. Customise your formula with a long-established solution that counters bitterness and improves taste.

Whether it is mini-tablets, lozenges, chewable tablets, sachets, effervescents, galenIQ™ – pharmaceutical grade of Isomalt – is available in different grades, fitting a wide range of applications.

Learn how galenIQ™ can be applied as an oil-carrier in liquisolid systems and improve taste and mouthfeel in probiotic and pediatric medicine

As part of the Südzucker Group, BENEO GmbH offers a pharma grade excipient derived from the sugar beet: galenIQTM. This highly functional filler-binder is characterised by its good flavour, ease of use and applicability to a wide range of solid and liquid dosage forms such as tablets, sachets, lozenges and syrups. In addition, it is also low-glycaemic and non-cariogenic.

Grades:

The galenIQ™ range includes agglomerated grades 720 and 721, which are excellent filler-binders for direct compression and powder mixture applications/sachets. In addition, the 900 series is also highly suitable for capsule fillings, dry suspensions, sugar-free coatings and high-boiled lozenges.

Thanks to its versatility, galenIQ™ obtained the 2009 Frost & Sullivan Product Innovation Award. galenIQ is manufactured under cGMP conditions according to IPEC-PQG requirements for pharmaceutical excipients and complies with the current Ph. Eur., BP, USP-NF and JP monographs for Isomalt.
phone +49 621 421 150
email contact@beneo.com
web www.beneo.com/ingredients/pharmaceutical-excipients
email Maximilianstrasse 10, 68165 Mannheim, Germany
 
spacer

Member login

E-mail address:

Password:
Remember me

Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 
News and Press Releases

Biosimilar Drug Development the analytical strategy is keyfactor for your success

Heilbronn/Dortmund March 2019: The generation of analytical data for the comparison between a biosimilar and the originator product is the initial assumption in the development of biosimilars. Achieving Biosimilarity can be a controversial and complex topic when deciding the right time point and range of analytics.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement